<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119786">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543490</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-305-001</org_study_id>
    <nct_id>NCT01543490</nct_id>
  </id_info>
  <brief_title>Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects</brief_title>
  <acronym>ISV-305</acronym>
  <official_title>A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (Dexamethasone in DuraSite®) Compared to Vehicle in the Treatment of Subjects With Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSite Vision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSite Vision</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305
      (Dexamethasone in DuraSite®) compared to Vehicle in the treatment of subjects with
      Non-Bacterial Blepharitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Resolution</measure>
    <time_frame>Day 15</time_frame>
    <description>The primary efficacy endpoint for the comparison of ISV-305 and Vehicle is complete clinical resolution of signs and symptoms at Day 15.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>ISV-305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISV-305</intervention_name>
    <description>Dexamethasone in DuraSite® twice daily for 2 weeks</description>
    <arm_group_label>ISV-305</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Placebo twice daily for 2 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are at least 18 years of age.

          -  Signature of the subject or legally authorized representative on the Informed Consent
             Form.

          -  Are willing and able to follow all instructions and attend all study visits.

          -  Are willing to avoid disallowed medication for the duration of the study

          -  If female is of childbearing potential, agree to and submit a urine sample for
             pregnancy testing and use effective contraception for the duration of the study.

          -  Additional inclusion criteria also apply.

        Exclusion Criteria:

          -  Have known sensitivity or poor tolerance to any component of the study drugs.

          -  Have had eyelid surgery in the study eye within twelve (12) months prior to Visit 1
             or during the study.

          -  Have an acute ocular infection (bacterial, viral or fungal) or active ocular
             inflammation other than blepharitis in the study eye.

          -  Have used topical corticosteroid medications or topical ophthalmic solutions that the
             investigator feels may interfere with the study parameters within 14 days of
             enrollment.

          -  Be currently pregnant, nursing, or planning a pregnancy; or have a positive urine
             pregnancy test.

          -  Have prior (within 30 days of beginning study treatment) or anticipated concurrent
             use of an investigational drug or device.

          -  Have a condition or a situation which, in the investigator's opinion, may put the
             subject at increased risk, confound study data, or interfere significantly with the
             subject's study participation.

          -  Additional exclusion criteria also apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charlotte Baenziger</last_name>
    <email>charlotte.baenziger@sunpharma.com</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>February 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
